Ireland
--:--IST
Latest
Clinical Trials in France / NCT04618016
Active, not recruiting Observational

Evaluation of Medium Cross-linked Polyethylene With and Without Vitamin E for Total Knee Arthroplasty

NCT04618016 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2021-03-08
Last updated
2026-02-27

Condition(s) studied

Osteoarthritis, KneeArthritis, RheumatoidIntra-Articular FracturesJoint InstabilityGenu Valgum or Varum

Investigational drug(s) / intervention(s)

UHMWPE with Vitamin EUHMWPE without Vitamin E

UHMWPE with Vitamin E: e.motion Pro (PS and UC) with MXE gliding surface

UHMWPE without Vitamin E: e.motion Pro (PS and UC) with β-PE gliding surface

Study summary

Prospective, randomized, single-blind, multinational, long-term study for the evaluation of the clinical outcome, oxidation profile and wear analysis of medium cross-linked Polyethylene with and without Vitamin E for total knee arthroplasty

Eligibility

Sex
ALL
Min age
18 Years
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: * Indication for a total knee replacement with a mobile-bearing UC or PS inlay * Written informed consent for participating at the clinical study * Willingness and mental ability to participate at the long-term follow-up examinations Exclusion Criteria: * Patient age \< 18 and \> 80 years * Pregnancy * High risk patients (ASA class \>3)

Primary outcome measure(s)

Trial sites (8)

FacilityCityRegionStatus
Hôpital Sud - CHU de Grenoble Échirolles Isere
CHU Amiens-Picardie Amiens France
Lukas Krankenhaus Bünde North Rhine-Westphalia
Brüderhaus Koblenz Koblenz Rhineland-Palatinate
Park-Klinik Weißensee Berlin Germany
Waldkliniken Eisenberg Eisenberg Germany
Krankenhaus Reinbek, St. Adolf Stift Reinbek Germany
Universitätsklinikum Rostock, Klinik für Orthopädie Rostock Germany

More Aesculap AG trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04618016 on ClinicalTrials.gov ↗ ← All trials in France